SRG rat available for order now

Hera BioLabs is a contract research organization (CRO) utilizing revolutionary gene editing technologies to create enabling preclinical research models for oncology & immuno-oncology. Hera’s platform model, the SRG rat™, is a SCID rat on the Sprague-Dawley background harboring a double knockout for the Rag2 and Il2rgamma genes. This enhanced immunodeficient rat model has a severely impaired immune system lacking B-cells, T-cells, and NK-cells. The SRG rat overcomes limitations of mouse models such as NSG mice and the less immunodeficient Nude rat. For example, the SRG rat enables tumor cell line xenograft models that were previously inefficient or not feasible in mouse models. While the long timeline required for the establishment of patient derived xenografts or PDX models in mice is often impractical; the SRG rat grows ~10x larger tumors enabling PDX establishment and efficacy studies in fewer passages and a shorter amount of time.

 

In published data the SRG rat has demonstrated key advantages for use in preclinical trials. Superior xenograft take rates, growth kinetics and larger sample sizes make for powerful tumor models in the SRG rat. Humanized mouse models have been utilized for immuno-oncology studies. The immune system of the SRG rat has been successfully humanized as first published in our American Association for Cancer Research (AACR) EORTC NCI poster. The humanized SRG rat may be an alternative model to humanized mice and syngeneic mouse models.

 

Hera is providing the SRG rat off-the-shelf as well as running preclinical studies to produce high-confidence, translational data. As a complement to our SRG rat platform services, we have experience in commercially available models such as NSG mice, SCID mice, NOD SCID mice and the Nude rat. In addition to oncology services, we have successfully humanized the liver of the TK-NOG mouse for toxicology and metabolism studies.

Latest Hera News

  • Humanized immune-system SRG Rats™ & mice for immuno-oncology - The SRG rat demonstrates robust immune-system humanization with peripheral blood mononuclear cells, the huPBMC-SRG rat™. First published in Hera's 2017 AACR-EORTC-NCI Molecular Targets poster Novel immunodeficient rat models offers a unique platform for drug efficacy studies in human tumor xenografts. Humanized SRG rats may have advantages in immuno-oncology, in particular for tumor models with low take-rates in mice. Hera is Continue Reading >
  • Hera Presents at SOT 2017 & AACR 2017 Recap - Hera strives to provide its clients with superior preclinical toxicology and efficacy research from model creation to data delivery.  Below are the summaries of our presentations from the Society of Toxicology – Annual Meeting 2017 and the American Association for Cancer Research – Annual Meeting 2017. Effect of Transfecting HepG2 with Human CYP Enzymes on Chemical Toxicity (SOT 2017) HepG2, Continue Reading >
  • Chimeric Humanized Mouse Models: Understanding Human and Mouse Cell Interactions - Humanized liver mouse models are increasingly being used in preclinical trials and have allowed for groundbreaking in-vivo research to evaluate everything from human-specific drug toxicity and efficacy to gene therapies. Unlike their transgenic mouse model counterparts, chimeric liver mouse models that include human hepatocytes and it is important for researchers to better understand the interactions between the implanted human cells Continue Reading >

Preclinical Oncology Insights

Check out the latest updates from our monthly newsletter which provides information on new R&D, publications, model development & industry trends in the three categories below.

  • Understanding Transporter-Mediated Drug-Drug Interactions Using Humanized Liver Mice - Pharmaceutical researchers and regulators are increasingly aware of the influence that transporters have on the pharmacokinetics of drugs. These transporter mediated drug-drug interactions (DDIs) can precipitate adverse reactions in patients and as a result, safety guidelines across the United States, Europe and Japan have been updated to require safety assessments of DDIs in large scale clinical trials of pharmaceuticals.   Continue Reading >
  • Using Patient Derived Xenografts to Improve Therapeutic Cancer Treatments - An increased understanding of human tumors has created a solid foundation for the creation of new anti-cancer treatments (many of which involve antineoplastic compounds). And while many of these newly conceived drug therapies show profound responses in preclinical trials, this has not translated into significant progress in the clinical setting. In fact, less than 5% of such treatments showed efficacy Continue Reading >
  • Humanized Mouse Models Advance Immunotherapeutic Strategies in Treatment of Type 1 Diabetes - A relatively common autoimmune disease, Type 1 Diabetes (T1D) is still not well understood. It is known that T1D is caused by immune destruction of insulin-producing β cells and although it is widely believed that autoreactive T cells recognizing β cell antigens (eg. insulin) play a critical role in the disease onset and progression, researchers still have little direct evidence Continue Reading >